Carlyle Group (NASDAQ:CG) Bolsa

Carlyle Group

The Carlyle Group is one of the world's largest alternative-asset managers, with $447.4 billion in total AUM, including $313.6 billion in fee-earning AUM, at the end of September 2024. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure, and natural resources funds (accounting for 33% of fee-earning AUM and 57% of base management fees during 2023), global credit (51% and 27%) and investment solutions (16% and 16%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 2,900 active carry fund investors from 88 countries.

The Carlyle Group Inc

A2B Australia Ltd DR

The Carlyle Group Inc. - 4.625% Subordinated Notes due 2061

CODE GREEN APPAREL by Code Green Apparel Corp.

Code Green Apparel Corp

CONCORDE GAMING CORP by Concorde Gaming Corp.

Concorde Gaming Corp

CHINA RES GAS UNSP/ADR by China Resources Gas Group Ltd

China Resources Gas Group Ltd

Centerra Gold Inc

Carlyle Secured Lending, Inc. - Closed End Fund

Carlyle Secured Lending Inc

Carlyle Secured Lending, Inc. - 8.20% Notes due 2028

Capital Group Core Balanced ETF

Crown LNG Holdings Limited - Ordinary Shares

Crown LNG Holdings Ltd

Canopy Growth Corporation - Common Shares

Canopy Growth Corp

Capital Group Core Bond ETF

CENTRAL GLASS CO LTD ORD by Central Glass Co., Ltd.

Central Glass Co Ltd

Commerce Group Corp

Capital Group Core Plus Income ETF

Capital Group Conservative Equity ETF

CARLIN GOLD CORP NEW by Carlin Gold Corp.

Carlin Gold Corp

Capital Group Dividend Growers ETF

CHINA GROWTH DEV INC by China Growth Development, Inc.

CONROY GOLD & NATURAL RES by CONROY GOLD AND NATURAL RESOURES PLC

Conroy Gold and Natural Resources PLC

CHENGDU SIWI SCI & TECH by CHENGDU SIWI SCIENCE & TECHNOLOGY CO LTD

Chengdu SIWI Science & Technology Co Ltd

Capital Group Dividend Value ETF

Xali Gold Corp

COGECO COMMUNICATIONS ORD by Cogeco Communications Inc

Cogeco Communications Inc

Cogeco Inc

CGN NEW ENERGY HLDGS LTD by CGN New Energy Holdings Ltd

CGN New Energy Holdings Co Ltd

CAPSTONE GREEN ENERGY CP by Capstone Green Energy Corporation

Capstone Green Energy Holding Inc

CGE Energy Inc

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics Inc

Capgemini SE

Compugen Ltd

CF Energy Corp

CHUGIN FINL GROUP INC by CHUGIN FINL GROUP INC.

ChainGuardians

Capital Group Global Equity ETF

Coats Group PLC

Capital Group Global Growth Equity ETF

Capital Group Growth ETF

Viridien ADR

CAPITAL GROUP HLDGS INC by Capital Group Holdings, Inc.

Capital Group Holdings Inc

CHAARAT GOLD HLDGS LTD by CHAARAT GOLD HOLDINGS LIMITED

CHINA GAS HLDGS LTD ADR by China Gas Holdings Ltd.

China Gas Holdings Ltd

Capital Group Municipal High-Income ETF

CHINA GAS HLDGS LTD ORD by China Gas Holdings Ltd.

Capital Group International Bond ETF (USD-Hedged)

Capital Group International Core Equity ETF

Capital Group International Equity ETF

Chemtrade Logistics Income Fund

Celadon Group Inc

ESR-REIT

CARGOJET INC VARIABLE VTG by Cargojet, Inc.

Cargojet Inc

CHUGOKU ELEC POWER CO by Chugoku Electric Power Company

Chugoku Electric Power Co Inc

CHUGOKU ELEC PWR UNSP/ADR by Chugoku Electric Power Company

CITIGROUP KOREA INC GDR by Citigroup Korea, Inc.

Cassiar Gold Corp

Buscar Co

Celo - United States Dollar

Coro Global Inc

CHINA MINSHENG BKNG ORD by China Minsheng Banking Corp., Ltd.

China Minsheng Banking Corp Ltd

CHALICE MINING LTD by Chalice Mining Ltd.

Chalice Mining Ltd

Capital Group Equity ETF Trust I Capital Group U.S. Small and Mid Cap ETF

Capital Group U.S. Multi-Sector Income ETF

Capital Group Municipal Income ETF

Capital Group New Geography Equity ETF

CARDIOGENICS HLDGS INC by CardioGenics Holdings Inc.

CardioGenics Holdings Inc

CGN MINING CO LTD by CGN MINING COMPANY LTD.

CGN Mining Co Ltd

COGNETIVITY NEUROSCIENCES by Cognetivity Neurosciences Ltd.

Cognetivity Neurosciences Ltd

Cognyte Software Ltd

CGN Power Co Ltd

Cognex Corp

Calamos Global Total Return Fund - Closed End Fund

Calamos Global Total Return Fund

Contact Gold Corp

CG Oncology Inc

GRAND PHARMACEUTICAL GRP by GRAND PHARMACEUTICAL GROUP LIMITED

Grand Pharmaceutical Group Ltd

Viridien

C&C Group PLC

CGROWTH CAPITAL INC by CGrowth Capital, Inc.

CGrowth Capital Inc

CANADIAN GENL INVTS LTD by Canadian General Investments, Limited

Capstone Green Energy Corp

Tidal Trust II CoreValues Alpha Greater China Growth ETF

CHARACTER GROUP PLC by Character Group PLC

Character Group (The) PLC

CannaGrow Holdings Inc

CORPORATIVO FRAGUA by Corporativo Fragua S.A. de C.V.

Corporativo Fragua SAB de CV

Capital Group Short Duration Income ETF

Country Garden Services Holdings Co Ltd ADR

CGS International Inc

Capital Group Short Duration Municipal Income ETF

CENTERGISTIC SLTNS INC by Centergistic Solutions, Inc.

CHINA TOPREACH INC ORD by China TopReach Inc.

CACHE Gold

Creative Global Technology Holdings Limited - Ordinary Shares

Creative Global Technology Holdings Ltd

GT Resources Inc

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics Inc

WIIM

AGMH

ALLY

ARES

BBAR

BBDO

DAVE

DOMH

FRHC

HOOD

IBKR

MUFG

NRDS

OSCR

ROOT

SLQT

SOFI

UPST

Shares of companies in the broader financial sector are trading lower amid overall market weakness on US consumer and economic concerns.

Bluebird Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>), on Friday, entered into a definitive agreement to be acquired by global investment firms Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">and </a><a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">SK Capital Partners</a><a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">.</a>
The agreement, which also includes a team of biotech executives, will see Bluebird Bio&#8217;s stockholders receive $3.00 per share in cash, along with a contingent value right, which could potentially bring the total payout to up to $9.84 per share, depending<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43878541/bluebird-bio-announces-definitive-agreement-to-be-acquired-by-carlyle-and-sk-capital" rel="noreferrer noopener"> on the product portfolio performance.</a>
The acquisition will provide Bluebird Bio with capital to scale its commercial delivery of gene therapies for patients suffering from sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Following the acquisition&#8217;s completion, former Mirati Therapeutics CEO David Meek is expected to take over as Bluebird Bio&#8217;s new CEO.
This strategic acquisition comes after Bluebird Bio&#8217;s financial struggles, including the denial of a priority review voucher by the FDA and mounting challenges that could have led to a loan default.
This strategic acquisition comes after Bluebird Bio&#8217;s challenges, including the denial of a priority review voucher by the FDA and mounting financial&nbsp;issues that could have led to a loan default.
Also Read:<a target="_blank" href="https://www.benzinga.com/tech/25/02/43876492/apples-visual-intelligence-may-come-to-iphone-15-pro-heres-how-it-can-transform-your-camera-with-ai-powered-real-time-search" rel="noreferrer noopener"> Apple&#8217;s Visual Intelligence May Come To iPhone 15 Pro: Here&#8217;s How It Can Transform Your Camera With AI-Powered Real-Time Search</a>
The deal is anticipated to close in the first half of 2025, subject to regulatory approvals and customary closing conditions.
&#8220;For more than a decade, bluebird has been at the forefront of gene therapy, delivering groundbreaking treatments to patients facing life-threatening genetic diseases,&#8221; said Andrew Obenshain, current CEO of Bluebird Bio. &#8220;However, as our financial challenges mounted, it became clear that securing the right strategic partner was critical to maximizing value for our stockholders and ensuring the long-term future of our therapies.&#8221;
Upon completion of the deal, bluebird will become a privately held company, and its shares will no longer be publicly traded.
In addition, Bluebird Bio has entered into amendments to its loan agreement with Hercules Capital to facilitate adequate liquidity to position it to maintain operations through the closing.
Price Action: BLUE shares traded lower by 37.5% to $4.40 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty" target="_blank" rel="noreferrer noopener">Institutional Investors Load Up On Technology And Financial Stocks In Q4 While Reducing Positions In Healthcare Sector Amid Political Uncertainty</a></li>
</ul>
Photo via Shutterstock.

Equities

News

Markets

Movers

General

BLUE

What's Going On With Gene Therapy Company Bluebird Bio Stock Today?

Carlyle Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CG#NYSE">CG</a>) short percent of float has fallen 6.7% since its last report. The company recently reported that it has 8.86 million shares sold short, which is 4.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Carlyle Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740145522_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Carlyle Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Carlyle Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Carlyle Group's peer group average for short interest as a percentage of float is 3.15%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What's Driving the Market Sentiment Around Carlyle Group?

Under the terms of the agreement, bluebird stockholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December 31, 2027, for a potential total value of up to $9.84 per share in cash, subject to the tender of a majority of the outstanding shares of bluebird, receipt of applicable regulatory approvals, and other customary closing conditions.

Comments

Carlyle Group

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL